Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
Good morning, everyone. Damian Garde here, filling in for Ed Silverman on the back half of what is, at least in this part of the world, a shortened work week. Temperatures are climbing and with them ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback